Systematic Review of Binge Eating Rodent Models for Developing Novel or Repurposing Existing Pharmacotherapies

Gregory Berger; Joshua D Corris; Spencer E Fields; Lihong Hao; Lori L Scarpa; Nicholas T Bello

doi:10.3390/biom13050742

Systematic Review of Binge Eating Rodent Models for Developing Novel or Repurposing Existing Pharmacotherapies

Biomolecules. 2023 Apr 25;13(5):742. doi: 10.3390/biom13050742.

Authors

Gregory Berger¹, Joshua D Corris¹, Spencer E Fields^{2

3}, Lihong Hao², Lori L Scarpa², Nicholas T Bello^{1

4}

Affiliations

¹ Endocrinology and Animal Biosciences Graduate Program, Department of Animal Sciences, School of Environmental and Biological Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.
² Department of Animal Sciences, School of Environmental and Biological Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.
³ Nutritional Sciences Graduate Program, School of Environmental and Biological Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.
⁴ Rutgers Brain Health Institute, Rutgers University and Rutgers Biomedical and Health Sciences, Piscataway, NJ 08854, USA.

Abstract

Recent advances in developing and screening candidate pharmacotherapies for psychiatric disorders have depended on rodent models. Eating disorders are a set of psychiatric disorders that have traditionally relied on behavioral therapies for effective long-term treatment. However, the clinical use of Lisdexamfatamine for binge eating disorder (BED) has furthered the notion of using pharmacotherapies for treating binge eating pathologies. While there are several binge eating rodent models, there is not a consensus on how to define pharmacological effectiveness within these models. Our purpose is to provide an overview of the potential pharmacotherapies or compounds tested in established rodent models of binge eating behavior. These findings will help provide guidance for determining pharmacological effectiveness for potential novel or repurposed pharmacotherapies.

Keywords: Prozac; Vyvanse; binge; bulimia nervosa; eating pathologies; fluoxetine; mouse; rat.

Publication types

Review
Systematic Review
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Binge-Eating Disorder* / diagnosis
Binge-Eating Disorder* / drug therapy
Binge-Eating Disorder* / psychology
Bulimia Nervosa* / diagnosis
Bulimia Nervosa* / psychology
Bulimia Nervosa* / therapy
Bulimia* / diagnosis
Bulimia* / psychology
Bulimia* / therapy
Cognitive Behavioral Therapy*
Humans

Grants and funding

This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Peer-Reviewed Medical Research Program under W81XWH-19-1-0016. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense.